MedPath

Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections

Not Applicable
Recruiting
Conditions
Peripancreatic Fluid Collections
Pancreatic Fluid Collections
Endoscopic Ultrasound-Guided Drainage
Acute Pancreatitis
Interventions
Procedure: Early drainage of peripancreatic fluid collections
Registration Number
NCT05281458
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Brief Summary

Acute pancreatitis is a complex gastrointestinal disease with a variable course that is often difficult to predict early in its development. The majority of cases are mild, self-limited, and follow an uncomplicated course. However, 10-20% of cases can be associated with pancreatic or peripancreatic fluid collections, or both. Infected necrosis complicates 10% of all acute pancreatitis episodes and is associated with a mortality of 15-20%. Current guidelines for necrotizing pancreatitis recommend to postpone drainage until 4 or more weeks after initial presentation to allow collections to "walled-off". However, evidence of infection with clinical deterioration despite maximum support may mandate earlier intervention. It is unclear whether such delay is needed for drainage or whether earlier endoscopic intervention could actually be beneficial in the current approach. The aims of this randomized, controlled, multicenter study is to evaluate whether early endoscopic drainage in patients with peripancreatic fluid collection is superior to postponed intervention in the current practice.

Detailed Description

EUS guided drainage is now the preferred route for peripancreatic fluid collections (PFC). It belongs to transmural drainage and is accomplished by creating a fistula and placing a stent between the gastric or duodenal lumen and the PFC. The size of the PFC and percentage of solid debris were noted prior to puncture, and the optimal site of transluminal puncture was identified using EUS. Participants will be randomly allocated to either the intervention or the control group. Participants in the intervention group will undergo EUS guided drainage earlier (≤1 weeks) in the disease course. The follow-up duration is 6 months from randomization. All patients undergo imaging (contrast enhanced computed tomography) at 3- and 6-months post randomization.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Adult patients with PFC;
  • All patients with PFC will be screened for eligibility including a protocolized approach;
  • Patients admitted within 72 hours of onset
Exclusion Criteria
  • More than 30 days after onset of acute pancreatitis
  • Pregnant women
  • Documented chronic pancreatitis
  • Inability to gave informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Early endoscopic interventions for APEarly drainage of peripancreatic fluid collectionsParticipants in the intervention group will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
Primary Outcome Measures
NameTimeMethod
Number of Participants with New-onset multi-organ failure after intervention1-4 week
Changes in the Bedside Index of Severe Acute Pancreatitis (BISAP)1-4 week

Comparison of BISAP changes between the two groups after different treatments. Also compare the number of participants with BISAP ≥3. BISAP was designed as a predictor of mortality based on 5 variables: blood urea nitrogen (BUN) level greater than 25 mg/dL, impaired mental status, systemic inflammatory response syndrome (SIRS), age older than 60 years, or radiographic evidence of pleural effusion within the first 24 hours of admission. A BISAP score of 3 or greater was associated with developing organ failure, and a higher scores mean a worse outcome.

Secondary Outcome Measures
NameTimeMethod
Related complications1 month
Rates of mortality6 months
Length of ICU staysup to 3 months
Length of hospital stay3 months

Trial Locations

Locations (1)

Shanghai General Hospital, Shanghai Jiaotong University School of Medicine

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath